ANI Pharmaceuticals, Inc.
ANIP
$95.20
-$0.15-0.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.23% | 3.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.23% | 3.44% | |||
| Cost of Revenue | 2.16% | -9.02% | |||
| Gross Profit | 10.21% | 12.50% | |||
| SG&A Expenses | 8.12% | 8.79% | |||
| Depreciation & Amortization | 1.70% | 1.29% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.73% | -3.66% | |||
| Operating Income | 1.11% | 881.16% | |||
| Income Before Tax | -47.34% | 245.23% | |||
| Income Tax Expenses | -54.11% | 223.52% | |||
| Earnings from Continuing Operations | -45.48% | 252.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -45.48% | 252.60% | |||
| EBIT | 1.11% | 881.16% | |||
| EBITDA | 1.47% | 57.04% | |||
| EPS Basic | -47.20% | 227.31% | |||
| Normalized Basic EPS | 16.69% | 264.30% | |||
| EPS Diluted | -47.28% | 224.80% | |||
| Normalized Diluted EPS | 16.54% | 260.69% | |||
| Average Basic Shares Outstanding | 1.16% | 0.83% | |||
| Average Diluted Shares Outstanding | 1.31% | 3.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 0.84% | 1.66% | |||